Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2026 07:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
January 08, 2026 05:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.